Scientific Programme - Virtual Conference

All times are Central European Summer Time (CEST)

Live Talks will be available onDemand at the end of the respective Session 

Live Presentations

Friday, October 2, 2020

 

08.50 – 09.00                       Welcome Addresses

                                               Michael von Bergwelt, Mario Sznol

 

09.00 – 10.45                      Session 1: Emerging Concepts / New Agents

                                               Chair: Michael von Bergwelt, Christoph Zielinski

 

09.00 – 09.15                       The CD47-SIRPa myeloid immune checkpoint in cancer

                                               Timo K. van den Berg, Amsterdam, The Netherlands

 

09.15 – 09.30                       Potential of ADAR Pathway in immunotherapy

                                               Jeffrey Ishizuka, Boston, MA, USA

 

09.30 – 09.45                       L1 - TGF-beta blocks type I IFN release and tumor rejection in spontaneous mammary

 tumors

 Nadege Bercovici, Paris, France

 

09.45 – 10.00                       L2 - In vivo live imaging of human T/B cell lymphoma cross-linking mediated by bispecific

 CD20-TCB antibody
 
Floriana Cremasco, Schlieren, Switzerland

 

10.00 – 10.15                       CXCR3 required for anti-PD-1 efficacy

                                               Andrew Luster, Boston, MA, USA

 

10.15 – 10.30                       L3 - Update of the OpACIN and OpACIN-neo trials: 36-months and 18-months relapse-free

 survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

 patients

                                               Judith Versluis, Amsterdam, The Netherlands

 

10.30 – 10.45                       T cell bispecific antibodies (4-1BB and tumor antigen)

                                               Pablo Umana, Zurich, Switzerland

 

10.45 – 11.15                       Coffee Break

 

11.15 – 12.30                      Session 2: Microbiome and immunotherapy

                                               Chair: Dirk Haller, Nicola Segata

 

11.15 – 11.30                       Microbiome and Immunotherapy in Cancer

                                               Giorgio Trinchieri, Bethesda, MD, USA

 

11.30 – 11.45                       Computational metagenomics for uncovering the unexplored microbiome diversity

                                               Nicola Segata, Trento, Italy

 

11.45 – 12.00                       Microbial-derved metabolites in allo-transplant and anti-tumor immunity

                                               Hendrik Poeck, Munich, Germany

 

12.00 – 12.15                       Microbiome and epithelial cell stress in colon cancer

                                               Dirk Haller, Munich, Germany

 

12.15 – 12.30                       Microbiome modulation in HSC transplantation

                                               Marcel van den Brink, New York, NY, USA

 

12.30 - 13.00                        Satellite Symposium

 Please click HERE for more information

13.00 – 13.30                       Lunch Break

13.30 – 15.00                      Session 3: Tumor microenvironment

                                               Chair: Jürgen Ruland, Eric Tartour

 

13.30 – 13.45                       The role of the microbiome in modulating the efficacy of anti-PD-1 therapy

                                               Vyara Matson, Chicago, IL, USA

13.45 – 14.00                       Immunoscore as possible predictive marker of response to treatments

                                               Franck Pagès, Paris, France

 

14.00 – 14.15                       Tumor intrinsic vs tumor extrinsic immune suppression

                                               Kai Wucherpfennig, Boston, MA, USA

 

14.15 – 14.30                       Arming oncolytic viruses for DC activation and recruitment in melanoma

                                               T.D. de Gruijl, Amsterdam, The Netherlands

 

14.30 – 14.45                       Dissecting the interplay between tumor cells and the immune system melanoma

                                               progression and response to therapy

                                               Marisol Soengas, Madrid, Spain

 

14.45 – 15.00                       Pancreatic Cancer Tumor Microenvironment

                                               Lei Zheng, Baltimore, MD, USA

 

15.00 – 15.30                       Coffee Break

 

15.30 – 16.15                      Session 4: Vaccine Therapy

                                               Chair: Barbara Seliger, Lei Zheng

 

15.30 – 15.45                       Mucosal vaccinations for cancer treatment

                                               Georg Stary, Vienna, Austria

 

15.45 – 16.00                       Multiple antigen-engineered DC vaccines promoting antitumor immunity in melanoma

                                               Lisa Butterfield, San Francisco, CA, USA

 

16.00 – 16.15                       Vaccine therapy in reversing anti -PD1 resistance

                                               Samir Khleif, Washington, DC, USA

 

16.15 – 16.45                      Session 5: Pro & Contra Session: Blinatumomab vs anti-CD19 CAR T cells: which treatment

  should be preferred and when? Can we treat with either regimen after relapse on the other?

                                               Chair: Hermann Einsele, Dominik Wolf

 

16.15 – 16.30                       Pro Bite

                                               Dominik Wolf, Innsbruck, Austria

 

16.30 – 16.45                       Pro CAR

                                               Marion Subklewe, Munich, Germany

 

16.45 – 17.15                       Coffee Break

 

17.15 – 18.00                      Session 6: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

                                               Chair: Lisa Butterfield, José Saro

 

17.15 – 17.30                       High dimensional Immune Monitoring of Clinical Trials to Advance Human Immunotherapy

                                               Pier Federico Gherardini, San Francisco, CA, USA

 

17.30 – 17.45                       Hyperprogressive disease in patients treated with Immune checkpoint inhibitors

                                               Giuseppe Lo Russo, Milan, Italy

 

17.45 – 18.00                       Identifying Breast Cancer Specific Isoforms

                                               Jacques Banchereau, Bar Harbor, ME, USA

 

 

SATURDAY, OCTOBER 3, 2020

 

08.30 – 09.00                      Session 7: “Lost in Translation”

                                               Chair: Philipp Beckhove, Hendrik Poeck

 

08.30 – 08.45                       Ups and downs of IDO inhibition in cancer treatment

                                               George Prendergast, Philadelphia, PA, USA

 

08.45 – 09.00                       Why adoptive T cell therapies fail solid tumors?

                                               Sebastian Kobold, Munich, Germany

 

09.00 – 09.30                      Satellite Symposium

Please click HERE for more information

 

09.30 – 10.15                      Session 8: Lifetime Achievement Award

                                               Chair: Michael von Bergwelt

 

                                               The 34th anniversary of interleukin 6; a major player in inflammation, autoimmunity

  and cancer

                                               Toshio Hirano, Chiba, Japan

 

10.15 – 10.45                       Coffee Break

 

10.45 – 11.45                      Session 9: Cell Therapy in Solid Tumors

                                               Chair: Pedro Romero, Per Thor Straten

 

10.45 – 11.00                       Challenges of T-cell therapy in solid tumors

                                               Cassian Yee, Houston, TX, USA

 

11.00 – 11.15                       Novel CAR formats for solid tumors

                                               Sidi Chen, West Haven, CT, USA

 

11.15 – 11.30                       Novel strategies to enable T cell therapy of cancer

                                               Per Thor Straten, Herlev, Denmark

 

11.30 – 11.45                       CAR T cell therapy in non hematological pediatric cancer

                                               Franco Locatelli, Rome, Italy

 

11.45 - 12.15                      Satellite Symposium

Please click HERE for more information

12.15 – 12.45                       Lunch Break

 

12.45 – 13.30                      Session 10: Cell Therapy in Haematologic Diseases

                                               Chair: Florian Bassermann, Hinrich Abken

 

12.45 – 13.00                       Cell therapy of hematological malignancies

                                               Chiara Bonini, Milan, Italy

 

13.00 – 13.15                       New targets and technologies for CAR-T

                                               Michael Hudecek, Würzburg, Germany

 

13.15 – 13.30                      L4 - Synthetic agonistic receptor-activating BiTEs - a modular platform for the efficient

targeting of acute myeloid leukemia

Mohamed-Reda Benmebarek, Munich, Germany

13.30 - 14.00                       Coffee Break

14.00 – 15.00                      Session 11: Combination Therapy

                                               Chair: Michael Bergmann, Samir Khleif

14.00 - 14.15                       Combination of innate immune stimulation with immune check point blockade for cancer

                                              therapy

                                              Simon Heidegger, Munich, Germany

14.15 - 14.30                       Chemotherapy and antiPD-1 neoadjuvant Triple negative breast Cancer

                                              Marleen Kok, Amsterdam, The Netherlands

14.30 - 14.45                       L5 - RIG-I activation enhances melanoma immunogenicity and improves anti-tumor T cell

responses in combination with anti-PD-1 immune checkpoint blocking antibodies
Beatrice Thier, Essen, Germany

14.45 - 15.00                       Interaction of the Immune-System and irradiated Tumor cells

                                              Claus Belka, Munich, Germany

15.00 - 15.30                      Session 12: Best Poster Awards & Closing Remarks

                                              Chair: Volkmar Nüssler

ITOC7 has been granted 10 European CME credits

On-Demand Satellite Symposium

Please click HERE for more information

On-Demand Talks

Tumor microenvironment

  • O1 - Tumor lactic acidosis alters decisive T cell activities

Angelika Fischbeck, Munich, Germany

 

Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

  • O2 - Directly Linking Single T Cell Phenotype and Function to Genotype

Yelena Bronevetsky, Emeryville, United States

  • O3 - High-dimensional analysis of tumor architecture predicts cancer immunotherapy response

Christian Schürch, Stanford, United States

 

“Lost in Translation”

  • O4 - Mechanisms of lung cancer hyper-progression promoted by PD-1 immune checkpoint blockade

Amaia Martinez-Usatorre, Lausanne, Switzerland

 

 

Young Researcher Session

  • O5 - Deconstruction of hampered dendritic cell development by micro-environmental cross-talk in an organotypic human melanoma-in-skin model

Marta Lopez Gonzalez, Amsterdam, The Netherlands

 

Combination Therapy

  • O6 - Expression of anti-apoptotic gene cFLIP to enhance persistence in CAR T cells

Grace Tan, North Dunedin, New Zealand

 

  • O7 - A bispecific VHH approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2 T cells

Lisa King, Amsterdam, The Netherlands

 

  • O8 - Gemcitabine induces pro-apoptotic BH3 only proteins and sensitizes pancreatic ductal adenocarcinoma cells for RLH-triggered immunogenic cell death

Daniel Böhmer, Munich, Germany

 
 

e-POSTER PRESENTATIONS

P1 - Emerging concepts / novel agents

  • P01.01 - A Phase 1a/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Atif Abbas, Hopkinton, United States

  • P01.02 - HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer

Yan Asmann, Jacksonville, United States

 

  • P01.03 - VOC Pattern Recognition of Lung Cancer: a Comparative Evaluation of Different Dog- and eNose-Based Strategies Using Different Sampling Materials

Wiebke Biehl, Munich, Germany

 

  • P01.05 - Development of signal amplification for spatially-resolved, highly multiplexed biomarker analysis of human tumor tissues.

Oliver Braubach, Menlo Park, United States

  • P01.06 - Spatially-resolved, highly multiplexed biomarker analysis of cancerous and normal human breast tissues.

Oliver Braubach, Menlo Park, United States

  • P01.08 - Beyond PD-1: Characterization of new checkpoints restricting function of cytotoxic lymphocytes infiltrating human carcinoma

Anna Herbstritt, München, Germany

 

  • P01.09 - Dual signalling protein 107 triggers innate and adaptive immune response towards tumour cells

Lisa Jacob, Groningen, Netherlands

 

  • P01.10 - IFNy secretion of adaptive and innate immune cells as a parameter to display leukaemia derived dendritic cell (DCleu) mediated immune responses in AML

Lara Klauer, Munich, Germany

  • P01.11 - Role of Exosomes as promotors or biomarkers to study activation of leukemia-derived dendritic cells (DCleu)-mediated antileukemic activation of adaptive and innate immune-reactive cells against AML-blasts

Lin Li, Munich, Germany

  • P01.12 - Impact of complementary substances on immune cell activity

Martin Luzbetak, Munich, Germany

  • P01.13 - MERTK signaling is critical for T cell proliferation and memory

Richard Powell, Herlev, Denmark

  • P01.14 - Excessive biological ageing of circulating neutrophils in cancer promotes tumor progression

Christoph Reichel, Munich, Germany

  • P01.15 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature - the DONIMI study

Irene Reijers, Amsterdam, Netherlands

  • P01.16 - Effects of the STAT3 inhibitors on senescent tumour cells

Olena Sapega, Prague, Czech Republic

  • P01.17 - Tim-3/Galectin-9 pathway controls the ability of malignant cells to escape host immune surveillance. Regulatory mechanisms and therapeutic targets

Vadim Sumbayev, Chatham Maritime, United Kingdom

  • P01.18 - Metabolic status and immune activation influence clinical outcomes in patients after allogeneic hematopoietic stem cell transplantation

Sebastian Theurich, Munich, Germany

  • P01.20 - Tim-3-galectin-9 immunosuppressive pathway in human liquid and solid tumours

Inna Yasinska, Chatham Maritime, United Kingdom

  • P01.22 - Extending CAR T cell therapy applications via drug inducible control of transgene expression

Bettina Kotter, Bergisch Gladbach, Germany

  • P01.23 - Creating a cell-culture based reporter system for the evaluation of molecular signaling mechanisms of inhibitory chimeric antigen receptors

Maximilian Funk, Vienna, Austria
 

  • P01.24 - The selective HDAC6 inhibitor ITF3756 increases the differentiation to central memory T cells with reduced exhaustion phenotype

Gianluca Fossati, Cinisello Balsamo, Italy
 

P2 - Microbiome and immune system/immunotherapy

  • P02.01 - Predictive impact of the gut microbiota on treatment response to CD19 specific CAR T-cells

Viktoria Blumenberg, Munich, Germany

  • P02.02 - Generating neo- and self-antigen screening libraries for class II HLA presentation

Veronica Pinamonti, Heidelberg, Germany

  • P02.03 - Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma

Martin Thelen, Köln, Germany

P3 - Tumor microenvironment

  • P03.01 - Prevalence of CD112R+ immune cells in normal lymphatic tissues, inflammation and the cancer microenvironment

Niclas Blessin, Hamburg, Germany

  • P03.02 - Suppression of T-cell proliferation and cytokine release by the adenosine axis are mediated by different mechanisms

Julia Festag, PLANEGG/ MARTINSRIED, Germany

  • P03.03 - Organization, function and gene expression of tertiary lymphoid structures in PDAC resembles lymphoid follicles in secondary lymphoid organs

María García-Márquez, Cologne, Germany

  • P03.04 - Applying Multispectral Unmixing and Spatial Analyses to Explore Tumor Heterogeneity with a Pre-Optimized 7-color Immuno-Oncology Workflow

Virginie Goubert, Marlborough, United States

  • P03.05 - Deep Spatial Profiling of the Immune Landscape of MSI and MSS Colorectal Tumors

Mathias Holpert, Seattle, United States

  • P03.06 - Pattern of Ki67+ expanding CD8+ cytotoxic T cells in healthy tissues, inflammation and the cancer microenvironment

Claudia Hube-Magg, Hamburg, Germany

  • P03.07 - Fast automated microfluidic-based multiplexed immunofluorescence for tumor microenvironment analysis

Alexandre Kehren, Lausanne, Switzerland

  • P03.10 - Prevalence and prognostic role of FoxP3<sup>+</sup>regulatory T lymphocytes in cancer. A tissue microarray study on >20’000 cancers

Tim Mandelkow, Hamburg, Germany

  • P03.11 - Exploring tumor-intrinsic factors regulating the recruitment of myeloid-derived suppressor cells (MDSC) in pancreatic ductal adenocarcinoma

Carlotta Rambuscheck, München, Germany

  • P03.13 - Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and reduce response to immune-oncology treatments

Suzanne Sitnikova, Cambridge, United Kingdom

  • P03.15 - Site-specific immune evasion and substantial heterogeneity within entities provide evidence for personalized immunotherapy

Martin Thelen, 50931, Germany

  • P03.16 - Functional Defects in B-cells of Patients with von-Hippel-Lindau Syndrome

Sebastian Theurich, Munich, Germany

  • P03.17 - uPA-PAI-1 heteromers promote advanced stages of breast cancer by attracting pro-tumorigenic neutrophils

Bernd Uhl, München, Germany

  • P03.19 - Evaluation of immunogenicity differences in LLC1 and GL261 tumor models for effective chemo-immunotherapy treatment

Karolina Zilionyte, Vilnius, Lithuania

  • P03.20 - A murine, myc-driven lymphoma model expressing human CD22 enables testing of targeted therapies and their effects on tumor immune microenvironment
    Fabian Müller, Erlangen, Germany
     

  • P03.21 - Projecting T cells into a reference transcriptomic atlas to interpret antitumor immune responses

Santiago Carmona, Epalinges, Switzerland

 

  • P03.22 - Repolarization of tumor-associated macrophages for immunotherapy of tumors with diverse major histocompatibility complex class I expression
    Adrianna Piataková, Prague 2, Czech Republic
     

  • P03.23 - Evolution of the immune landscape within partially controlled murine melanoma
    Chen Qing, London, United Kingdom
     

  • P03.26 - Immunoprofiling of oral and oropharyngeal tumors of different etiology

Barbora Pokrývková, Vestec, Czech Republic
 

  • P03.27 - Role of NOX2 for hypoxia-induced chemoresistance in acute myeloid leukemia
    Sanchari Paul, Gothenburg, Sweden
     

  • P03.28 - Structural characteristics in tumor and lymph nodes as predictors of 3-year metastasis-free survival in surgically treated NSCLC
    Laura Sellmer, Munich, Germany
     

  • P03.29 - Characterization of treatment-induced adaptive immune responses in pancreatic ductal adenocarcinoma
    Jeannine Heetmeyer, München, Germany
     

  • P03.31 - Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy

Natasa Prokopi, Amsterdam, Netherlands

P4 - Vaccine Therapy

  • P04.01 - Dendritic-cell based immunotherapy targeting pancreatic and NSCLC cancer stem cells

João Calmeiro, Coimbra, Portugal

  • P04.02 - A novel Cancer immunotherapy combines rMVA-CD40L with tumor targeting antibodies

Maria Hinterberger, Martinsried, Germany

  • P04.03 - Immune modulatory vaccine directed against IDO1-expressing immune cells elicits T cell-mediated anti-tumor immunity and enhances anti-PD1 responses

Ayako Pedersen, Copenhagen, Denmark

  • P04.04 - Multifunctional antibody construct for in vivo targeting of dendritic cells as a therapeutic vaccination strategy in AML

Saskia Schmitt, München, Germany

  • P04.05 - Modulating tumor microenvironment with arginase-1 specific T cells
    Evelina Martinenaite, Copenhagen, Denmark
     

  • P04.06 - Mucosal immunization with a cDC1-targeted CTA1 adjuvant vaccine confers protection against melanoma metastasis

Mohammad Arabpour, Göteborg, Sweden
 

  • P04.08 - Virus like vaccines: a novel immunotherapy strategy against the cancer-associated endogenous retrovirus

Joana Daradoumis, Copenhagen, Denmark
 

  • P04.09 - Development of a dendritic cell vaccine against hepatocellular carcinoma using VSV-NDV

Julia Gold, München, Germany

P5 - Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

  • P05.01 - Comparative analysis of RNA versus DNA as input material for IGH repertoire sequencing panels for immuno-oncology applications and rare clone detection

Geoffrey Lowman, Carlsbad, United States

 

P6 - Cell Therapy in Solid Tumors

  • P06.01 - Bispecific antibody-driven synthetic agonistic receptor - transduced T cells mediate specific and conditional therapy in melanoma cancer models

Mohamed-Reda Benmebarek, Munich, Germany

  • P06.02 - Enhancing CAR T cell persistence and memory through modulating mitochondrial function

Ali Hosseini Rad, Dunedin, New Zealand

  • P06.03 - C-C chemokine receptor 8 tumor-directed recruitment enables CAR T cells to reject solid tumors

Bruno L. Cadilha, München, Germany

  • P06.05 - IDO1-deleted CAR T cells show improved therapeutic efficacy in murine pancreatic cancer models

Anne Senz, München, Germany

  • P06.06 - Adoptive cell therapy of triple negative breast cancer with redirected Cytokine-Induced Killer cells

Annavera Ventura, Padova, Italy

  • P06.07 - CXCR6 expression enhances accumulation of anti-mesothelin CAR T cells at the tumor site and their therapeutic efficacy in pancreatic cancer xenografts

Adrian Gottschlich, Munich, Germany

  • P06.09 - Anti-hPSMA CAR engineered NK-92 cells: An off-the-shelf cellular therapeutic for targeted elimination of prostate cancer cells

Alessandro Penna, Padova, Italy

  • P06.10 - Short term inhibition of checkpoint proteins increases ex vivo expansion of tumour infiltrating lymphocytes in high grade serous ovarian cancer
    Caitlin Waddell, Manchester, United Kingdom
     

  • P06.11 - Immunotargeting of CD98hc for Elimination of Radioresistant Head and Neck Squamous Cell Carcinoma
    Ayse Köseer, Dresden, Germany
     

  • P06.12 - Combination therapy of CAR-NK-cells and anti-PD-1 antibody results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

Michael Burger, Frankfurt, Germany

 

  • P06.13 - A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells

Michael Burger, Frankfurt, Germany

 

  • P06.14 - Characterization of tumor-infiltrating T cells by highly multiplexed immunofluorescence imaging

Elvira Criado-Moronati, Bergisch Gladbach, Germany

 

  • P06.15 - Highly Multiplexed, Single-Cell Functional Proteomics of CAR-T Products Enables More Predictive Product Characterization, Cell Manufacturing Optimization, and Cellular Biomarkers across Product Types

Dong Liu, Branford, United States

P7 - Cell Therapy in Haematologic Diseases

  • P07.01 - CD19 CAR T-cells for relapsed/refractory Diffuse Large B-Cell Lymphoma: Real-world data from LMU Munich

Veit Bücklein, Munich, Germany

  • P07.02 - High-affinity TCRs specific for Cancer Testis Antigens as a therapy for multiple myeloma and solid tumors

Marije de Rooij, Leiden, Netherlands

 

P8 - Combination Therapy

  • P08.01 - Low-dose Checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavorable immunological profile (MSI low, PD-L1 under 1%, TMB low) - A single-institution experience from 2015 to 2020

Ralf Kleef, Vienna, Austria

  • P08.03 - Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy

Charlotte Pilard, Liège, Belgium

  • P08.04 - ​​Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial

Johannes Laengle, Vienna, Austria

 

P9 - Young Researchers Session

  • P09.01 - ​​Adoptive cell therapy of hematological malignancies using Cytokine-Induced Killer cells retargeted with monoclonal antibodies

Anna Dalla Pietà, Padua, Italy

  • P09.02 - ​​​Mapping and tackling tumor and chemotherapy-induced immune suppression in breast cancer sentinel lymph nodes

Natasa Prokopi, Amsterdam, Netherlands

  • P09.03 - ​​​Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma

Johannes Hildebrand, Munich, Germany

  • P09.04 - ​​​Oncolytic H5N1 influenza strain displays superior therapeutic properties independent of immuno-stimulatory interleukin-2 transgene expression

Julijan Kabiljo, Vienna, Austria

  • P09.05 - ​​​Immunogenicity induced by the academic Chimeric Antigen Receptor CAR19 (ARI-0001) in patients with CD19-positive relapsed/refractory B-cell malignancies recruited into the CART19-BE-01 clinical trial

Nela Klein-González, Barcelona, Spain

  • P09.06 - ​​​An enhanced CRISPR tool for treating chronic myelogenous leukemia

Duško Lainšček, Ljubljana, Slovenia

  • P09.07 - ​​​An immune modulatory vaccine targeting CCL22 promotes anti-tumor immunity

Inés Lecoq, København, Denmark

  • P09.08 - ​​​Clinical-grade manufacturing of ROR1 CAR T cells using a novel virus-free protocol

Katrin Mestermann, Würzburg, Germany

  • P09.09 - ​​​PD-1 checkpoint blockade for treatment of mucormycosis and invasive aspergillosis in a stem cell transplant recipient

Niklas Mueller, Munich, Germany

  • P09.10 - ​​​Local immunotherapy of brain cancer harnessing high-retention Fc-fusion constructs

Linda Schellhammer, Schlieren, Switzerland

  • P09.11 - ​​​TLR3 suppresses colorectal carcinogenesis, presumably through up-regulation of T-cell attracting CXC chemokines

Anna Sichler, München, Germany

  • P09.12 - ​​​Bifunctional SIRPα-CD123 fusion antibody for the elimination of acute myeloid leukemia stem cells

Siret Tahk, Munich, Germany

  • P09.13 - ​​​Optimization of a GMP-grade large-scale expansion protocol for Cytokine-Induced Killer cells using gas-permeable static culture flasks.

Annavera Ventura, Padua, Italy

  • P09.14 - ​​​Blocking counterregulation of unfolded protein response by targeted protein synthesis inhibition produces highly synergistic cell death in several cancer entities

Franziska Gsottberger, Erlangen, Germany

  • P09.15 - ​​​Targeting the stroma to enhance effector memory T cell infiltration and anti-tumor response to anti-PD1 antibody in pancreatic ductal adenocarcinoma

Arsen Osipov, Baltimore, United States

© 2020 WMA GmbH - ITOC7     |     Data Protection Policy

  • Twitter - Grau Kreis